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Reactive oxygen species (ROS)-inducing anticancer agents such as phenethylisothiocyanate (PEITC) activate stress pathways for
killing cancer cells. Here we demonstrate that PEITC-induced ROS decreased expression of microRNA 27a (miR-27a)/miR-20a:
miR-17-5p and inducedmiR-regulated ZBTB10/ZBTB4 and ZBTB34 transcriptional repressors, which, in turn, downregulate
specificity protein (Sp) transcription factors (TFs) Sp1, Sp3, and Sp4 in pancreatic cancer cells. Decreased expression of miR-27a/
miR-20a:miR-17-5p by PEITC-induced ROS is a key step in triggering the miR-ZBTB Sp cascade leading to downregulation of Sp
TFs, and this is due to ROS-dependent epigenetic effects associated with genome-wide shifts in repressor complexes, resulting in
decreased expression of Myc and theMyc-regulated miRs. Knockdown of Sp1 alone by RNA interference also induced apoptosis
and decreased pancreatic cancer cell growth and invasion, indicating that downregulation of Sp transcription factors is an im-
portant commonmechanism of action for PEITC and other ROS-inducing anticancer agents.
Reactive oxygen species (ROS), including radicals such as su-peroxide, nitric oxide, and hydroxyl radicals and nonradical
species such as hydrogen peroxide, ozone, and peroxynitrates,
function in normal cells to maintain homeostasis via redox path-
ways (1–3). In some cancer cell lines, a modest increase in forms of
ROS can enhance cell proliferation, survival, and drug resistance;
however, further increases in ROS that cannot be attenuated by
intracellular redox systems result in cell death (3). ROS levels are
higher in cancer than in noncancer cells, and drug-induced eleva-
tion of ROS is a “way to selectively kill cancer cells without causing
toxicity to normal cells” (3). Drug-induced ROS in cancer cells
may be due to inhibition or inactivation of redox pathway en-
zymes or due to direct effects on mitochondria, which include
opening of the permeability transition pore complex, resulting in
decreased mitochondrial membrane potential (MMP) and activa-
tion of proapoptotic cascades (3–5).
Several anticancer drugs that induce ROS, including arsenic
trioxide, the methyl ester of 2-cyano-3,12-dioxo-oleana-1,9-dien-
28-oic acid (CDDO-Me), curcumin, betulinic acid, a synthetic
nonsteroidal anti-inflammatory drug (NSAID) (GT-094), and
celastrol also downregulate specificity protein (Sp) transcription
factors Sp1, Sp3, and Sp4 and prooncogenic Sp-regulated genes
(6–11). Similar effects have been reported for H2O2, t-butylhy-
droperoxide, and pharmacologic doses of ascorbate that induce
H2O2 (12). Moreover, the effects of ROS inducers and prooxi-
dants on growth inhibition, induction of apoptosis, and down-
regulation of Sp proteins and Sp-regulated genes are attenuated
after cotreatment with antioxidants (6–12). Induction of ROS by
CDDO-Me, GT-094, betulinic acid, and celastrol decreases ex-
pression of Sp transcription factors through downregulation of
microRNA 27a (miR-27a) and/or miR-17/miR-20a and induc-
tion of the miR-regulated Sp repressors ZBTB10 and ZBTB4, re-
spectively (6–9). The relationship between drug-induced ROS and
disruption of miR-dependent suppression of ZBTB transcrip-
tional repressors suggests that this may be an important underly-
ing mechanism of action for other ROS-inducing anticancer
agents.
Phenethylisothiocyanate (PEITC) and other isothiocyanates
(ITCs) have been linked to the chemoprevention and anticancer
activity associated with consumption of cruciferous vegetables
(13–17). PEITC and other ITCs inhibit cancer cell growth, sur-
vival, and angiogenesis, and these activities are accompanied by
downregulation of total and activated STAT3 protein (18), sup-
pression of NF-B (and p65 downregulation) (16, 17), and de-
creased expression of epidermal growth factor receptor (EGFR)
(18), genes involved in migration/invasion (19, 20), and bcl-2 and
cyclins (21–23). Silencing of Sp1 and Sp1/Sp3/Sp4 (combined) by
RNA interference (RNAi) shows that many of these same genes
are regulated by Sp transcription factors in cancer cell lines (8–11,
24). PEITC and the related benzyl analog (BITC) also induce ROS
in many cancer cell lines (22, 25–29). In Ras-transformed ovarian
cancer cells, PEITC decreases intracellular glutathione (GSH) and
also inhibits glutathione peroxidase activity, resulting in the in-
duction of ROS and decreased MMP (25). In this study, we have
used PEITC as a model ROS inducer to test the hypothesis that an
important underlying mechanism of action of anticancer agents
that induce ROS is due to downregulation of Sp1, Sp3, Sp4, and
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Sp-regulated genes through disruption of miR-ZBTB interactions
and that this pathway is dependent on ROS-mediated epigenetic
modulation of Myc expression.
MATERIALS AND METHODS
Cell lines, reagents, and antibodies. The Panc28 cell line was a generous
gift from Paul Chiao (University of Texas M. D. Anderson Cancer Center,
Houston, TX), and the L3.6pL cell line was kindly provided by I. J. Fidler
(University of Texas M. D. Anderson Cancer Center). Panc1, SW480, and
RKO cells were obtained from the American Type Culture Collection
(Manassas, VA). The cells were maintained in Dulbecco’s modified Eagle
medium (DMEM)–Ham’s F-12 nutrient mixture (Sigma-Aldrich, St.
Louis, MO) with phenol red supplemented with 0.22% sodium bicarbon-
ate, 5% fetal bovine serum (FBS), and 10 ml/liter 100 antibiotic/anti-
mycotic solution (Sigma-Aldrich). Cells were grown in 150-cm2 culture
plates in an air-CO2 (95:5) atmosphere at 37°C and passaged approxi-
mately every 3 to 5 days. Antibodies to survivin and CD1 were from
Epitomics (Burlingame, CA); vascular endothelial growth factor (VEGF)
was from Rockland (Gilbertsville, PA); cleaved poly(ADP-ribose)
polymerase (cPARP), cMet, and cMyc were from Cell Signaling (Bos-
ton, MA); VEGF receptor 1 (VEGFR1) and ZBTB34 were from Abcam
(Cambridge, MA); ZBTB10 was from Bethyl Laboratories Inc. (Mont-
gomery, TX). All other antibodies were purchased from Santa Cruz
(Santa Cruz, CA). Glutathione (GSH; 98% pure) and PEITC (99%
pure) were purchased from Sigma-Aldrich. Sp1 and chemilumines-
cence reagents (Immobilon Western) for Western blot imaging were
purchased from Millipore (Billerica, MA). Lipofectamine 2000 was
purchased from Invitrogen (Carlsbad, CA). HPDE cells were provided
by M. S. Tsao, University of Toronto (Toronto, ON, Canada), and S.
Srivastava, Texas Tech University (Amarillo, TX).
Cell proliferation assay. Pancreatic cancer cells (4  104 per well)
were plated in 12-well plates and allowed to attach for 24 h. The medium
was then changed to DMEM–Ham’s F-12 mixture without phenol red
containing 2.5% charcoal-stripped FBS, and either vehicle (dimethyl sul-
foxide [DMSO]) or different concentrations of compounds in DMSO
were added. Cells were then trypsinized and counted after 24, 48, and 72 h
using a Coulter Z1 cell counter. Pancreatic cancer cells (1.5 105 per well)
were plated in 12-well plates and allowed to attach for 24 h. Cells were
pretreated with GSH for 3 h and were either dosed with PEITC alone or
cotreated with PEITC and GSH. Cells were trypsinized and counted after
24 h using the Coulter Z1 cell counter. Each experiment was done in
triplicate, and results are expressed as means  standard errors (SE) for
each set of experiments.
Western blot analysis. Pancreatic cancer cells were seeded in 6-well
plates using 2.5% DMEM–Ham’s F-12 medium, and after 24 h, cells were
pretreated with GSH for 3 h. Cells were then treated with vehicle (DMSO)
and PEITC alone or cotreated with PEITC and GSH for the indicated
time, and Western blot analysis of whole-cell lysates was performed es-
sentially as described previously (8, 10, 11).
Measurement of mitochondrial membrane potential. MMP was
measured with a mitochondrial membrane potential detection kit (Strat-
agene, Cedar Creek, TX) according to the manufacturer’s protocol using
JC-1 dye. Pancreatic cancer cells were plated on 2-well Lab-Tex Coverglass
slides (Nunc, NY), and after 24 h, cells were treated with DMSO or PEITC
alone or PEITC in combination with GSH for 24 h. Cells were then incu-
bated with 1 JC-1 dye at 37°C for 15 min, washed twice with assay buffer,
and analyzed microscopically for changes in MMP essentially as described
previously (10).
ROS determination. Cellular ROS levels were evaluated with the cell-
permeable probe CM-H2DCFDA [5-(and 6)-chloromethyl-2=,7=-dichlo-
rodihydrofluorescein diacetate acetyl ester]. Cells were seeded at a cellular
density of 1.5  105 cells/ml in 6-well plates, allowed to attach for 24 h,
pretreated with GSH for 3 h, and treated with vehicle (DMSO), PEITC
alone, or PEITC plus GSH for the indicated times. ROS was determined by
flow cytometry as described previously (6).
TEM. Cells were seeded at a cellular density of 1 105 cells/ml using
2.5% DMEM–Ham’s F-12 in Permanox 2-well chambered slides. Cells
were pretreated with GSH and then dosed with vehicle (DMSO) and
PEITC alone or cotreated with PEITC and GSH for the indicated time.
After dosing, cell cultures were fixed in 2% glutaraldehyde, 2.5% parafor-
maldehyde, and 0.1 M sodium cacodylate buffer for 1 h at room temper-
ature. After washing in buffer, the cell monolayers were poststained with
1% osmium tetroxide reduced by 0.2% potassium ferrocyanide for 1 h
and then dehydrated in an ascending alcohol series and embedded in
epoxy resin. Thin sections were cut en face, stained with 2% uranyl acetate
and Reynold’s lead citrate, and then examined with an FEI Morgagni 268
transmission electron microscope (TEM) at an accelerating voltage of 80
kV. Digital images were acquired with a MegaViewIII camera operated
with iTEM software (Olympus Soft Imaging Systems, Germany) and then
postprocessed with Adobe Photoshop.
Annexin V staining. Panc1, Panc28, and L3.6pL cells (1.5  105/ml)
were pretreated and dosed with either vehicle or PEITC alone or in combina-
tion with GSH for 24 h. Cells were then stained using the Vybrant apoptosis
assay kit according to the manufacturer’s protocol (Biotium, CA).
RT-PCR. Total RNA was isolated using the mirVana miRNA isolation
kit (Ambion, Austin, TX) according to the manufacturer’s protocol. RNA
was eluted with 100l of RNase-free water and stored at80°C. RNA was
reverse transcribed using the Verso cDNA synthesis kit (Thermo scien-
tific, PA) according to the manufacturer’s protocol. Real-time (RT)-PCR
was carried out using Sybr green (Life Technologies, NY). The following
primers were used: TBP (F), 5=-TGCACAGGAGCCAAGAGTGAA-3=; BP
(R), 5=-CACATCACAGCTCCCCACCA-3=; ZBTB10 (F), 5=-GCTGGAT
AGTAGTTATGTTGC-3=; ZBTB10 (R), 5=-CTGAGTGGTTTGATGGAC
AGA-3=; ZBTB4 (F), 5=-ACCTGTGCAGGAATTTCCAC-3=; ZBTB4 (R),
5=-GAGCGGCCAAGTTACTGAAG-3=; ZBTB34 (F), 5=-GCCAGCTTTC
TTCAGATGCAGTG-3=; and ZBTB34 (R), 5=-CTCTTCAGCACCGACG
GTAACA-3=.
Quantification of miRNA (RNU6B and miR-17, -20a, and -27a) was
done using the TaqMan miRNA assay kit (Life Technologies) according to
the manufacturer’s protocol with real-time PCR. U6 small nuclear RNA
was used as a control to determine relative miRNA expression.
RNA interference and miR mimic assays. Small interfering RNAs
(siRNAs) for Myc and GL2 were purchased from Sigma-Aldrich. The
siRNA complexes used in this study are as follows: siGL2-5=, CGU ACG
CGG AAU ACU UCG A; siMyc, SASI_Hs01_00222676.
The Panc1, Panc28, and L3.6pL pancreatic cancer cell lines were
seeded (6 104 per well) in 6-well plates in DMEM–Ham’s F-12 medium
supplemented with 2.5% charcoal-stripped FBS without antibiotic and
left to attach for 1 day. The Myc siRNA knockdown with siGL2 as a control
was performed using Lipofectamine 2000 transfection reagent as per the
manufacturer’s instructions. The effects of miR mimics and antagomirs
were determined as previously described (6–9, 30, 31).
ChIP assay. The chromatin immunoprecipitation (ChIP) assay was
performed using the ChIP-IT Express magnetic chromatin immunopre-
cipitation kit (Active Motif, Carlsbad, CA) according to the manufactur-
er’s protocol. Panc1 cells (5 106 cells) were treated with 20 M PEITC
for 3 h. Cells were then fixed with 1% formaldehyde, and the cross-linking
reaction was stopped by addition of 0.125 M glycine. After washing twice
with phosphate-buffered saline, cells were scraped and pelleted. Collected
cells were hypotonically lysed, and nuclei were collected. Nuclei were then
sonicated to the desired chromatin length (200 to 1,500 bp). The soni-
cated chromatin was immunoprecipitated with normal IgG (Santa Cruz),
c-Myc (Abcam), H3K27me3 (Abcam), H3K4me3 (Abcam), H4K16Ac
(Active Motif), or RNA polymerase II (pol II; GeneTex) antibodies and
protein A-conjugated magnetic beads at 4°C for overnight. After the mag-
netic beads were extensively washed, protein-DNA cross-links were re-
versed and eluted. DNA was prepared by proteinase K digestion followed
by PCR amplification. The primers for detection of the c-Myc promoter
region were 5=-GCC CTT TCC CCA GCC TTA GC-3= (sense) and 5=-
AAC CGC ATC CTT GTC CTG TGA GTA-3= (antisense), the primers for
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detection of the beta-actin (ACTB) promoter region were 5=-CTC CCT
CCT CCT CTT CCT CA-3= (sense) and 5=-TCG AGC CAT AAA AGG
CAA CTT-3= (antisense), the primers for detection of the Sp1 promoter
region were 5=-CTA ACT CCA ATC ATA ACG TTC C-3= (sense) and
5=-GAG CTG GAG ATG ATT GGC TTG-3= (antisense), the primers for
detection of the miR-23a/27a cluster promoter region were 5=-TAG AGG
ACC ACG TGT TCA TTT TGC-3= (sense) and 5=-TGT AAA ATG GAG
CCA AGA GCC TC-3= (antisense), and the primers for detection of the
miR-17/92 cluster promoter region were 5=-ACT TTG CAG TCT CGG
GTG TTC-3= (sense) and 5=-CGG GAT AAA GAG TTG TTT CTC
CAA-3= (antisense). PCR products were resolved on a 2% agarose gel in
the presence of ethidium bromide (EtBr).
Effects of Sp1 knockdownon cell proliferation, invasion, death, and
cycle analysis. Panc1 and L3.6pL cells were seeded in 12-well plates and
permitted to attach for 24 h, and then cells were transfected with 100 nM
siRNA control or siRNAs for Sp1 using Lipofectamine 2000 (Invitrogen,
Grand Island, NY). Cells were trypsinized and counted at the indicated
times using a Coulter Z1 cell counter (Beckman Coulter, Fullerton, CA).
For cell cycle analysis, cells were stained with propidium iodide solution
(50g/ml) and were analyzed by a FACSCalibur flow cytometer 24 h after
transfection. Apoptosis was detected using a fluorescein isothiocyanate
(FITC) annexin V staining kit (Life Technologies, Grand island, NY) fol-
lowed by fluorescence-activated cell sorter (FACS) analysis according to
the manufacturer’s protocol. Panc1 and L3.6pL cells were transfected with
Sp1 siRNAs or a nonspecific control siRNA, and after 32 h, a cell invasion
assay was performed as previously described (32).
Xenograft study. Female athymic nude mice, 4 to 6 weeks old, were
purchased from Harlan Laboratories (Houston, TX). L3.6pL cells (3 
105) in a 1:1 ratio of Matrigel (BD Biosciences) were injected into either
side of the flank area of nude mice. Seven days after the tumor cell inoc-
ulation, mice were divided into two groups of 10 animals each. The first
group received 100l vehicle (corn oil), and the second group of animals
received an injection of 60 mg/kg of body weight/day of PEITC in corn oil
every 2nd day for 18 days (9 doses) by intraperitoneal (i.p.) injection. The
mice were weighed, and the tumor areas were measured throughout the
study. After 20 days, the animals were sacrificed; final body and tumor
weights were determined and plotted. Research involving animal experi-
mentation was reviewed and approved by the Texas A&M University In-
stitutional Animal Care and Use Committee.
Statistical analysis. Statistical significance of differences between the
treatment groups was determined by an analysis of variance and/or Stu-
dent’s t test, and levels of probability were noted. Fifty percent inhibitory
concentrations (IC50s) were calculated using linear regression analysis
and expressed in M, at 95% confidence intervals.
RESULTS
Inhibition of cell and tumor growth and induction of ROS. Ini-
tial studies showed that PEITC inhibited proliferation of Panc1,
L3.6pL, and Panc28 pancreatic cancer cells after treatment for 1, 2,
or 3 days. Growth inhibition after treatment for 24 h was observed
for 20 M PEITC in all cell lines, and 10 M PEITC also signifi-
cantly inhibited growth in L3.6pL and Panc28 cells (Fig. 1A). In
contrast, only minimal inhibition of nontransformed HPDE pan-
creatic cells was observed after treatment with 10 or 20M PEITC
(see Fig. S1A in the supplemental material). PEITC (60 mg/kg/
day) also inhibited tumor growth in athymic nude mice bearing
L3.6pL cells as xenografts (Fig. 1A). The concentrations of PEITC
required for inhibition of pancreatic cell growth were slightly
higher than previously reported in prostate and bladder cancer
cells, and this was also confirmed in this study (see Fig. S1B and C
in the supplemental material). Subsequent in vitro cell culture
experiments primarily used 20 M PEITC, since the major focus
of this study was to investigate the mechanism of action of PEITC
and key early events that occur within 24 h after treatment. Using
the cell-permeant ROS-sensitive probe carboxy H2DCFDA, we
observed by FACS analysis that ROS was induced by PEITC in
L3.6pL, Panc1, and Panc28 cells after treatment for 3 or 6 h; in cells
cotreated with PEITC plus the antioxidant glutathione (GSH),
there was significant inhibition of ROS induction (Fig. 1B to D).
These data are consistent with the results observed in transformed
ovarian cancer cells, where PEITC rapidly depleted cellular GSH
due, in part, to direct inhibition of glutathione peroxidase activity
(25).
Effects of PEITC on mitochondrial structure, MMP, and
apoptosis: role of ROS. The effects of PEITC on mitochondrial
structure and integrity were examined by TEM. Initial studies in
L3.6pL cells showed that treatment with 20M PEITC for 1, 3, or
6 h resulted in a significant loss of mitochondrial architecture and
crista structure only after 6 h, and this response was attenuated
after cotreatment with GSH (Fig. 2A). A similar approach was
used for Panc28 and Panc1 cells (Fig. 2A), and the PEITC-induced
mitochondrial damage observed after treatment for 6 h was atten-
uated in cells cotreated with PEITC plus GSH (Fig. 2B). The effects
of PEITC on mitochondria were further investigated by determin-
ing the effects of this compound on loss of mitichondrial mem-
brane potential (MMP) using the JC-1 dye and determining JC
aggregates (red mitochondrial fluorescence indicating high
MMP)/JC monomer (green cytoplasmic fluorescence caused by
collapse of mitochondrial potential) ratios (Fig. 2C). MMP was
not decreased in any of the cell lines after treatment with PEITC
for 3 h (data not shown); however, Fig. 2C illustrates the earliest
time points at which PEITC decreased MMP in L3.6pL (6 h),
Panc28 (12 h), and Panc1 (12 h) cells, and these effects were at-
tenuated after cotreatment with GSH, confirming the importance
of PEITC-induced ROS in mediating mitochondrial damage in
pancreatic cancer cells. These results show that PEITC induces
ROS prior to loss of MMP and damage to mitochondria, and these
results are consistent with a previous report showing that PEITC
rapidly induces extramitochondrial ROS in transformed cell lines
(25).
PEITC also induced annexin V staining in Panc1, L3.6pL, and
Panc28 cells (Fig. 3A to C), and this apoptotic response was signifi-
cantly blocked in cells cotreated with GSH; moreover, GSH also at-
tenuated PEITC-induced growth inhibition (Fig. 3D), confirming
that PEITC-induced ROS plays an essential role in the antineoplastic
activity of this compound in pancreatic cancer cells, and similar re-
sults have previously been reported in other cancer cell lines treated
with PEITC or BITC (22, 25–29). While it is clear that induction of
ROS can induce mitochondrial damage, cellular stress, and apopto-
sis, other pathways and genes responsible for the cytotoxicities of
PEITC and other ROS inducers are not well defined.
PEITC downregulates Sp1, Sp3, Sp4, and Sp-regulated gene
products. Previous studies in this laboratory show that ROS-in-
ducing anticancer agents betulinic acid, celastrol, and CDDO-Me
(all triterpenoids) and the nitro-NSAID GT-094 decrease expres-
sion of Sp transcription factors (6–12), and therefore, the effects of
PEITC on expression of Sp1, Sp3, Sp4, and Sp-regulated gene
products were also investigated. Treatment of L3.6pL, Panc1, and
Panc28 cells with 10 or 20 M PEITC for 24 h decreased levels of
Sp1, Sp3 (low- and high-molecular-weight forms), and Sp4 pro-
teins (Fig. 4A). PEITC also decreased expression of the survival
gene products bcl-2 and survivin, poly(ADP-ribose) polymerase
(PARP) cleavage (Fig. 4B), and downregulated growth-promot-
ing (cyclin D1 and epidermal growth factor receptor [EGFR]) and
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angiogenic (vascular endothelial growth factor [VEGF] and
VEGFR1) gene products (Fig. 4C). We also observed that PEITC-
induced downregulation of Sp1, Sp3, and Sp4 proteins was re-
versed in L3.6pL, Panc1, and Panc28 cells cotreated with PEITC
plus GSH (Fig. 4D), confirming a role for ROS in mediating re-
pression of Sp transcription factors, and this correlated with the
role of ROS in PEITC-induced apoptosis and growth inhibition in
pancreatic cancer cells (Fig. 3). PEITC also decreased expression
of Sp1, Sp3, and Sp4 proteins in tumors from athymic nude mice
bearing L3.6pL cells as xenografts (Fig. 4E).
FIG 1 PEITC inhibits pancreatic cancer cell growth and induces ROS. (A) L3.6pL, Panc28, and Panc1 cells were treated with different concentrations of PEITC
for up to 72 h, and cells were counted as outlined in Materials and Methods. Relative tumor weights after treatment with PEITC or corn oil (control) were
determined as outlined in Materials and Methods, and a significant (P 0.05) decrease in weight is indicated (*) (10 animals per treatment group). L3.6pL (B),
Panc28 (C), and Panc1 (D) cells were treated with 20M PEITC, GSH, or their combination for 3 and 6 h, and ROS was determined by FACS analysis using the
cell-permeant CM-H2DCFDA dye as described in Materials and Methods; effects observed after 3 and 6 h were quantitated (similar results were obtained in
duplicate experiments).
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The effects of PEITC and other ROS inducers, including ben-
zylisothiocyanate (BITC) and piperlongumine (33), on decreased
expression of Sp1, Sp3, and Sp4 and the reversal of this response
by GSH were confirmed in other cancer cell lines. PEITC and
BITC decreased expression of Sp1, Sp3, and Sp4 in RKO and
SW480 colon cancer cells (see Fig. S2 in the supplemental mate-
rial), and similar effects were observed for PEITC and BITC in
253JB-V and KU7 bladder (see Fig. S3 in the supplemental mate-
rial) and L3.6pL pancreatic and KU7 bladder (see Fig. S4 in the
supplemental material) cancer cells, respectively. Piperlongumine
also decreased Sp1, Sp3, and Sp4 expression in Panc1 and L3.6pL
cells (see Fig. S5 in the supplemental material). The downregu-
lation of Sp proteins by PEITC, BITC, and piperlongumine was
attenuated after cotreatment with antioxidants, and we also
observed induction of ROS by these compounds (data not
shown).
FIG 2 PEITC disrupts mitochondrial structure and decreases MMP. L3.6pL, Panc28, and Panc1 cells were treated with 20 M PEITC alone (A) or in
combination with GSH (B), and mitochondrial ultrastructure was determined by TEM as outlined in Materials and Methods. The widths of the fields are 2 m
(A) and 5.3m (B). (C) Cells were treated with DMSO (solvent), 20M PEITC, or 5 mM GSH or GSH plus PEITC for the indicated times, and changes in MMP
were determined by JC-1 staining as outlined in Materials and Methods. Results are means SE (3 replicates per data point), and significant (P 0.05) inhibition
(*) and reversal of the effect by GSH (**) are indicated. Red, JC-1 aggregates; green, JC-1 monomers.
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Prooncogenic activity of Sp1, Sp3, and Sp4: RNAi studies.
The functional importance of downregulation of Sp1, Sp3, Sp4,
and prooncogenic Sp-regulated genes by ROS-inducing antican-
cer agents was further investigated by RNA interference (RNAi) in
pancreatic cancer cells using Sp1 as a model. Silencing of Sp1 by
RNAi in Panc1 and L3.6pL cells significantly decreased cell prolif-
eration (Fig. 5A), cell cycle progression (Fig. 5B), and invasion
in a Boyden chamber assay (Fig. 5C) and induced apoptosis
FIG 3 Glutathione inhibits PEITC-induced apoptosis and growth inhibition. (A to C) L3.6pL (A), Panc28 (B), and Panc1 (C) cells were treated with 20 M
PEITC or GSH alone or in combination, and annexin V staining was determined as outlined in Materials and Methods. (D) Cell proliferation. Cells were treated
as described for panels A to C for 24 h; cells were then counted as outlined in Materials and Methods. Results are means SE (3 replicates for each data point),
and significant (P 0.05) effects by PEITC (*) and attenuation by cotreatment with GSH (**) are indicated.
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(Fig. 5D). These results demonstrate that Sp1 is a prooncogenic
factor, indicating that downregulation of Sp1, other Sp transcrip-
tion factors, and Sp-regulated genes by ROS-inducing anticancer
agents is an important underlying mechanism of action for these
compounds.
ROS-dependent disruption of miR-ZBTB interactions. Pre-
vious studies show that ROS-dependent downregulation of Sp1,
Sp3, and Sp4 in pancreatic and other cancer cells was due to down-
regulation of miR-27a and/or miR-20a/miR-17, resulting in the
induction of miR-regulated “Sp repressors” ZBTB10 and ZBTB4,
FIG 4 PEITC downregulates Sp1, Sp3, Sp4, and Sp-regulated genes. (A to C) Pancreatic cancer cells were treated with different concentrations of PEITC for 24 h, and
whole-cell lysates were analyzed for Sp1, Sp3, and Sp proteins (A), prosurvival proteins (B), and growth-promoting and angiogenic proteins (C) by Western blotting as
outlined in Materials and Methods. (D) Cells were treated with PEITC or GSH alone or in combination, and cell lysates were analyzed by Western blotting as indicated
for panels A to C. Results are typical of duplicate analyses, which gave comparable results. (E) Western blots of tumor lysates from control and PEITC-treated animals
bearing L3.6pL cells as xenografts and protein quantitation relative to controls. Data shown in panels A to C were from the same experiment.
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respectively (6–12). These transcriptional repressors competi-
tively bind GC-rich Sp binding sites in promoters of Sp1, Sp3, Sp4,
and Sp-regulated genes, resulting in decreased transactivation (30,
31). Figure 6A shows that PEITC also downregulated miR-27a,
miR-20a, and miR-17 in L3.6pL, Panc28, and Panc1 cells, and
PEITC-dependent downregulation of these miRs in L3.6pL,
Panc28, and Panc1 cells was attenuated after cotreatment with
GSH (Fig. 6B), confirming that downregulation of the miRs by
PEITC was ROS dependent. PEITC induced ZBTB10 mRNA in all
three cell lines and ZBTB4 mRNA in Panc28 and L3.6pL cells. We
also examined other ZBTB family members that contained	6-bp
sequences in their 3= untranslated regions (UTRs) that comple-
mented miR-27a and miR-20a/miR-17 lead sequence motifs
and identified ZBTB34 as a potential miR-27a-regulated gene, and
ZBTB34 mRNA was also induced by PEITC in Panc1, Panc28, and
L3.6pL cells (Fig. 6C). Induction of ZBTB proteins by PEITC was
time and cell context dependent (Fig. 6D); maximal levels of
ZBTB10 and ZBTB34 were observed after 3 to 6 and 9 to 12 h,
FIG 5 (A and B) Prooncogenic activity of Sp1 in pancreatic cancer cells. Cell growth (A) and cell cycle progression (B). Panc1 and L3.6pL cells were transfected
with two different oligonucleotides that silence Sp1 (siSp1I and siSp1II), and cell proliferation and cell cycle progression were determined by cell counting or
FACS analysis as outlined in Materials and Methods. (C and D) Pancreatic cancer cell invasion and quantitation (C) and induction of apoptosis (D). Panc1 and
L3.6pL cells were transfected with siSpI or siSp1II, and inhibition of cell migration in a Boyden chamber assay and induction of apoptosis were determined and
quantitated relative to the control (siCT) as outlined in Materials and Methods. Results in panels A to C are expressed as means  SE for at least 3 replicate
determinations for each treatment group, and significant (P 0.05) increases (*) or decreases (**) compared to a control group (siCT) are indicated.
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respectively, in Panc1 cells, whereas levels of ZBTB4 were rela-
tively unchanged (0 to 12 h), and time-dependent induction of
ZBTB proteins also varied in Panc28 and L3.6pL cells. Overex-
pression of ZBTB10 and ZBTB4 decreases expression of Sp1, Sp3,
and Sp4 in cancer cell lines (30, 31), and the results shown in Fig.
S6 in the supplemental material show that overexpression of
ZBTB10, ZBTB4, and ZBTB34 also decreased expression of the
three Sp proteins in Panc1, Panc28, and L3.6pL cells. Regulation
of the ZBTB repressors was confirmed in studies using miR mim-
ics that decrease ZBTB4, ZBTB10, and ZBTB34 mRNA expression
(see Fig. S7A in the supplemental material) and antisense miRs
that increase ZBTB4, ZBTB10, and ZBTB34 gene expression (see
Fig. S7B in the supplemental material).
ROS-dependent downregulation of Myc. A recent study
showed that H2O2 induced genome-wide shifts of repressor com-
plexes from non-GC-rich to GC-rich sites in colon cancer cells,
and this resulted in decreased expression of several genes, includ-
ing Myc (34); it has previously been reported that Myc regulates
expression of multiple miRs, including miR-27a and miR-20a/
miR-17-5p, which are members of the miR-23a/27a/24-2 and
miR-17-92 clusters (35–37). PEITC rapidly decreased Myc pro-
tein levels within 3 h in all three cell lines; however, the rate of
FIG 6 PEITC disrupts miR-ZBTB interactions. (A) PEITC decreases miR expression. Pancreatic cancer cells were treated with 20 M PEITC for 24 h, and miR
expression was determined by real-time PCR as outlined in Materials and Methods. (B) GSH attenuates PEITC-mediated downregulation of miRs. Cells were
treated with 20M PEITC, 5 mM GSH alone, or PEITC and GSH in combination for 24 h and analyzed for miR expression as outlined for panel A. (C) Induction
of ZBTB expression. Cells were treated as described for panel B, and ZBTB4, ZBTB10, and ZBTB34 mRNA levels were determined by real-time PCR as outlined
in Materials and Methods, and significant induction is indicated (*) (means SE for 3 replicate determinations). (D) ZBTB protein expression. Cells were treated
with 20M PEITC for different times, and ZBTB protein expression was determined by Western blotting as outlined in Materials and Methods. Results for panels
A to C are expressed as means  SE for at least 3 replicate experiments for each treatment group; significant (P  0.05) PEITC-induced responses (*) and
attenuation by GSH (**) are indicated.
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decrease was slower in Panc28 cells. PEITC also decreased Myc
RNA levels in Panc1, Panc28, and L3.6pL cells (see Fig. S7C). In ad-
dition, Sp1 (but not Sp3 or Sp4) protein was also decreased in L3.6pL
and Panc1 cells within 3 h after treatment with PEITC (Fig. 7A). The
rapid downregulation of Sp1 is consistent with a report showing that
ROS induced chromatin-wide shifts of repressor complexes to some
GC-rich sites (34) since the Sp1 gene promoter contains multiple GC
boxes (38). We also observed that PEITC-mediated downregulation
of Myc (and induction of PARP cleavage) was attenuated in cells
cotreated with PEITC plus GSH (Fig. 7B).
Since ROS-mediated induction of Myc in SW480 colon cancer
cells was due to genome-wide shifts of repressor complexes (34),
we used a ChIP assay to determine changes in histone methyl-
ation/acetylation marks and pol II on the Myc gene in Panc1 cells
treated with DMSO (control) or PEITC for 3 h (Fig. 7C). Methyl-
ation marks (H3K27me3 and H3K4me) were unchanged; how-
ever, the activation mark H4K16Ac and pol II were decreased after
treatment with PEITC, and this is consistent with decreased Myc
expression. In contrast, pol II and H3K4me3 were decreased on
the Sp promoter, whereas pol II and the activation mark H4K16Ac
were decreased on the ACTB promoter and ACTB mRNA levels
were also decreased in SW480 cells treated with H2O2 (34). These
results suggest that changes in histone acetylation/methylation
marks in response to ROS are both gene and cell context specific.
We also observed that treatment of Panc1 cells with PEITC re-
sulted in loss of Myc (and pol II) from the miR-23a/27a/24-2 and
miR-17-92 promoters (Fig. 7D), which is consistent with PEITC-
mediated downregulation of Myc (Fig. 7A) and the corresponding
miRs (Fig. 6A).
These results indicate that Myc plays a key role in PEITC/ROS-
induced responses, and this was further investigated by RNAi.
Transfection of pancreatic cancer cells with siMyc decreased ex-
pression of miR-20a and miR-27a in Panc1, Panc28, and L3.6pL
cells (Fig. 8A). siMyc also induced expression of ZBTB10, ZBTB4,
FIG 7 PEITC-induced responses are due to downregulation of Myc. (A) Time course effects on Sp transcription factors and Myc. Cells were treated with 20M
PEITC for various times and analyzed by Western blotting as outlined in Materials and Methods. (B) GSH attenuates Myc downregulation by PEITC. Cells were
treated with 20M PEITC, or 5 mM GSH alone, or PEITC and GSH in combination for 24 h, and whole-cell lysates were analyzed by Western blotting as outlined
in Materials and Methods. (C and D) ChIP analysis of cMyc, Sp1, and ACTB (C) and the miR promoters (D). Cells were treated with 20 M PEITC for 3 h, and
histone methylation and acetylation marks on the Myc, ACTB, and Sp1 promoters (C) and Myc binding to the miR-23a/27a and miR-17-92 promoters (D) were
determined in ChIP assays as outlined in Materials and Methods. Results are representative of replicate assays, and the various primers used (C and D) are listed
in Materials and Methods.
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and ZBTB34 mRNA and protein in these cells; however, the mag-
nitudes of these responses were variable (data not shown) due to
the time-dependent induction of these repressors (Fig. 6D). Since
PEITC-/ROS-mediated downregulation of miRs triggers the
downstream effects on ZBTB and Sp proteins, we further con-
firmed the role of Myc in this response by overexpression studies.
PEITC-induced downregulation of miR-27a and miR-20a in
Panc1, Panc28, and L3.6pL cells was significantly reversed by
overexpression of Myc (Fig. 8B); moreover, Myc overexpression
also increased basal miR expression in these cells. The results
shown in Fig. 8C show that knockdown of Myc decreased Sp1,
Sp3, and Sp4 expression in Panc1, Panc28, and L3.6pL cells, and
FIG 8 Myc knockdown disrupts miR-ZBTB interactions and downregulates Sp proteins. (A) Knockdown of Myc by RNA interference (siMyc) in pancreatic
cancer cells decreases expression of miRs. Panc1, Panc28, and L3.6pL cells were transfected with siMyc or a nonspecific oligonucleotide (siCtrl), and expression
levels of miR-20a and miR-27a were determined by real-time PCR as outlined in Materials and Methods. (B) Myc overexpression inhibits PEITC-mediated
suppression of miR-20a and miR-27a. Panc1, Panc28, and L3.6pL cells were treated with 20 M PEITC and transfected with a Myc expression plasmid (pMyc)
or empty vector (pcDNA3), and miR-20a and miR-27a expression was determined by real-time PCR as outlined in Materials and Methods. (C) Myc knockdown
decreases Sp proteins in pancreatic cancer cells. Panc1, Panc28, and L3.6pL cells were transfected with siMyc or siLamin (control), and whole-cell lysates were
isolated and analyzed by Western blotting as outlined in Materials and Methods. (D) Proposed mechanism of ROS-induced downregulation of Sp transcription
factors. Results shown in panels A and B are means SE for replicate determinations, and significantly (P	 0.05) decreased expression (*) and rescue (**) are
indicated. Significant upregulation by Myc overexpression is indicated (***).
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this was accompanied by decreased expression of survivin and
VEGF in the three cell lines and of bcl-2 in L3.6pL and Panc28
cells. Like Myc, Sp1 expression is also rapidly decreased in L3.6pL
cells (Fig. 7A) due to ROS-induced changes in histone marks (Fig.
7C), and knockdown of Sp1 also decreases miR-27a/miR-20a ex-
pression in these cell lines. Figure 8D summarizes the pathway
resulting from induction of ROS by PEITC, and our results sug-
gest that this is a pathway common to ROS-inducing anticancer
drugs.
DISCUSSION
Sp1, Sp3, and Sp4 transcription factors are highly expressed in
cancer cells and tumors (6–12), and studies focused on Sp1 show
that this protein is a negative-prognostic factor for pancreatic and
gastric cancer patient survival (39–41) and that Sp1 expression is
critical for malignant transformation of human fibroblast cells
(42). Expression of Sp1 in rodents and humans decreases with age
(43–45), and the high tumor/nontumor ratio of Sp1 suggests that
Sp transcription factors are important drug targets for cancer che-
motherapy. Knockdown of Sp1, Sp3, and Sp4 alone or in combi-
nation with RNAi also decreases expression of several gene prod-
ucts involved in cancer cell growth (cyclin D1, C-MET, and
EGFR), survival (bcl-2 and survivin), angiogenesis (VEGF and
VEGF receptors), and inflammation (p65 and NF-B) (6–12, 24);
many of these genes are themselves individual targets for antican-
cer drugs. Moreover, knockdown of Sp1 alone in pancreatic can-
cer cells also inhibits growth, cell cycle progression, and migration
and induces apoptosis (Fig. 5). Carcinogen-induced transformed
fibrosarcoma cells that form tumors in nude mice lose their
tumorigenicity after knockdown of Sp1 (42). Several clinically
used and experimental anticancer drugs downregulate Sp1, Sp3,
and Sp4 proteins and prooncogenic Sp-regulated gene products in
cancer cell lines through multiple pathways that are dependent on
the drug and cell context. For example, curcumin induces protea-
some-dependent downregulation of Sp proteins in bladder cancer
cells (46), whereas in pancreatic cancer cells, the effects of curcu-
min on decreased expression of Sp1, Sp3, and Sp4 are ROS depen-
dent (11), and these effects are attenuated after cotreatment with
antioxidants.
Previous studies with PEITC and related ITCs show that these
compounds inhibit cancer cell growth and angiogenesis/invasion,
induce apoptosis, and decrease expression of several gene prod-
ucts, such as p65 (NF-B), bcl-2, cyclin, and EGFR, that are also
decreased in cancer cells after silencing Sp1 or Sp1/Sp3/Sp4 (com-
bined) (8–11, 24). The mechanisms of action of PEITC and related
ITCs are either ROS dependent or independent in different cancer
cell lines, and the ROS-mediated effects have been extensively in-
vestigated (25–29). For example, PEITC rapidly depleted intracel-
lular GSH and inhibited glutathione peroxidase activity in Ras-
transformed ovarian cells, and the subsequent induction of ROS
decreased MMP and activated the intrinsic apoptosis pathway
(25). PEITC also induced ROS and decreased MMP in bladder
and prostate cancer cells (26–28), and this was accompanied by
cytochrome c release from mitochondria and changes in mito-
chondrial proteins. PEITC also affected mitochondrial oxidative
phosphorylation in prostate cancer cells. In pancreatic cancer
cells, PEITC rapidly induced ROS (within 3 h) (Fig. 1B to D), and
using TEM, we also showed that PEITC did not significantly affect
mitochondrial ultrastructure until 6 h after treatment (Fig. 2).
Similar results were observed for MMP, which was decreased only
after 6 h (Fig. 2). These results, coupled with the protective
effects of the antioxidant glutathione, are comparable to the in-
duction of extramitochondrial ROS by PEITC in Ras-transformed
ovarian epithelial cells, which was then followed by ROS-medi-
ated mitochondrial damage (25).
Prooxidants such as H2O2 and t-butylhydroperoxide and
pharmacological doses of ascorbate decrease Sp1, Sp3, Sp4, and
Sp-regulated genes in cancer cell lines (10, 12), and ROS-inducing
anticancer agents, including betulinic acid, curcumin,
CDODA-Me (methyl 2-cyano-3,11-dioxo-18-olean-1,12-dien-
30-oate), arsenic trioxide, and celastrol, downregulate Sp tran-
scription factors (6–12). PEITC also induced ROS and ROS-de-
pendent downregulation of Sp1, Sp3, and Sp4 in pancreatic cancer
cells (Fig. 4). Similar results were observed for PEITC, BITC, and
piperlongumine in multiple cancer cell lines (see Fig. S2 to S5 in
the supplemental material). These data, coupled with the func-
tional effects of Sp1 knockdown in Panc1 cells (Fig. 5), support the
hypothesis that an important underlying mechanism of action of
ROS-inducing anticancer agents is due to downregulation of Sp
transcription factors. Thus, the effectiveness of ROS-inducing an-
tineoplastic drugs is due not only to ROS-dependent activation of
proapoptotic pathways, including mitochondrial damage and ac-
tivation of other stress response pathways, but also to downregu-
lation of Sp transcription factors and Sp-regulated genes.
High expression of Sp1, Sp3, and Sp4 in cancer cell lines is due,
in part, to microRNA-dependent regulation of the transcriptional
repressors ZBTB10 and ZBTB4, which do not contain transacti-
vation domains and competitively bind GC-rich promoter sites to
displace Sp proteins (30, 31). ZBTB10 expression is repressed by
miR-27a (30), and ZBTB4 is repressed by miR-20a and miR-17-
5-p (part of the miR-17-92 cluster) and other paralogs (31).
PEITC-/ROS-mediated downregulation of miR-27a and miR-
20a/miR-17-5p results in induction of ZBTB10 and ZBTB4, re-
spectively, and subsequent downregulation of Sp proteins, and
these responses are attenuated in cells cotreated with GSH. miR-
27a/20a antagomirs or overexpression of ZBTB10 or ZBTB4 also
decreases expression of Sp1, Sp3, and Sp4 proteins (30, 31), and in
this study, we also show that ZBTB34 is another miR-27a-regu-
lated Sp repressor that decreases expression of Sp1, Sp3, and Sp4
(see Fig. S6 in the supplemental material). Thus, miR-27a plays a
particularly important role in maintaining high levels of Sp1, Sp3,
and Sp4 expression in all three cell lines by regulating ZBTB10 and
ZBTB34 expression.
The key unknown link between induction of ROS and the
ZBTB repressors that downregulate expression of Sp1, Sp3, and
Sp4 is the mechanism associated with miR downregulation. A
recent study reported that treatment of colon cancer cells with
H2O2 results in relocation of large chromatin-associated repressor
complexes from non-GC-rich to high-GC-rich sites; genes with
GC-rich promoters such as Myc and ACTB are downregulated
(34). Treatment of L3.6pL, Panc1, and Panc28 cells with PEITC
resulted in rapid downregulation of Myc in all three cell lines, and
this was attenuated by GSH (Fig. 7B). Interestingly, Sp1 was also
decreased in Panc1 and L3.6pL cells within 3 h after PEITC treat-
ment (Fig. 7A), and these data are consistent with results obtained
for H2O2 in colon cancer cells (34) since Sp1 also has several GC-
rich cis-elements in its 5= region (38). The PEITC-/ROS-mediated
shift in histone marks associated with nuclear relocalization of
repressor complexes was also confirmed by ChIP assays on the
Myc and Sp1 promoters (Fig. 7C). These data, coupled with the
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effects of Myc knockdown on expression of Sp1, Sp3, Sp4, and
Sp-regulated gene products (Fig. 8C), suggest that in pancreatic
cancer cells, ROS also induces shifts in repressor complexes as
observed in colon cancer cells (34). Moreover, ROS-dependent
repression of Myc and decreased Myc binding to the miR-23a/
27a/24-2 and miR-17-92 promoters (Fig. 7D) are consistent with
downregulation of miR-27a and miR-20a/miR-17-5p (Fig. 6A),
which are members of two Myc-regulated miR clusters (35–37).
In summary, results of this study demonstrate that PEITC and
other ROS-inducing anticancer agents decrease expression of Sp1,
Sp3, Sp4, and prooncogenic Sp-regulated genes in pancreatic and
other cancer cell lines. Since knockdown of Sp1 alone by RNAi
decreases cancer cell growth and invasion and induces apoptosis
(Fig. 5), this indicates that downregulation of Sp transcription
factors by ROS-inducing anticancer agents contributes to their
anticancer activity. A key element in triggering this response is due
to ROS-mediated repression of Myc (and Sp1 in some cells) due to
epigenetic effects associated with changes in histone marks; this is
consistent with results of a recent study showing comparable ef-
fects with H2O2 in colon cancer cells (34). The ROS-dependent
loss of Myc decreases miR expression and disrupts miR-ZBTB
interactions, resulting in the induction of ZBTB repressors that
decrease expression of Sp1, Sp3, and Sp4 (Fig. 8D). These results
indicate that ROS-inducing anticancer agents may be particularly
efficacious for treating cancer patients that overexpress Sp1 (41)
and other Sp proteins, and the identification of this ROS-induced
pathway will be important for the design of combination thera-
pies, particularly since Sp proteins decrease expression of drug-
resistant genes such as those encoding survivin and multidrug-
resistant proteins (10, 12, 47).
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